S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Is New IPO Instacart Already Hitting Speed Bumps?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Things to know about California's new proposed rules for insurance companies
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Is New IPO Instacart Already Hitting Speed Bumps?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Things to know about California's new proposed rules for insurance companies
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Is New IPO Instacart Already Hitting Speed Bumps?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Things to know about California's new proposed rules for insurance companies
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Is New IPO Instacart Already Hitting Speed Bumps?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Things to know about California's new proposed rules for insurance companies
KB Home Price Weakness is a Signal to Buy this Cash Machine
NASDAQ:TXG

10x Genomics (TXG) Stock Forecast, Price & News

$41.35
-0.56 (-1.34%)
(As of 09/22/2023 ET)
Compare
Today's Range
$41.25
$42.50
50-Day Range
$41.35
$62.98
52-Week Range
$23.81
$63.57
Volume
1.05 million shs
Average Volume
909,323 shs
Market Capitalization
$4.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.73

10x Genomics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
42.0% Upside
$58.73 Price Target
Short Interest
Healthy
4.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
-0.14mentions of 10x Genomics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$4.68 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.76) to ($1.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

157th out of 965 stocks

Analytical Instruments Industry

9th out of 26 stocks


TXG stock logo

About 10x Genomics (NASDAQ:TXG) Stock

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Price History

TXG Stock News Headlines

WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
10x Genomics Surpasses 100 Xenium Analyzer Shipments
Barclays Keeps Their Buy Rating on 10x Genomics (TXG)
See More Headlines
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

TXG Company Calendar

Last Earnings
8/03/2023
Today
9/22/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Health Information Services
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TXG
Fax
N/A
Employees
1,243
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$58.73
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+42.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-166,000,000.00
Pretax Margin
-29.36%

Debt

Sales & Book Value

Annual Sales
$516.41 million
Book Value
$6.99 per share

Miscellaneous

Free Float
104,913,000
Market Cap
$4.86 billion
Optionable
Optionable
Beta
1.77
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Serge Saxonov Ph.D. (Age 46)
    Co-Founder, CEO & Director
    Comp: $837.68k
  • Dr. Benjamin J. Hindson Ph.D. (Age 48)
    Co-Founder, Pres, Chief Scientific Officer & Director
    Comp: $615.96k
  • Mr. Justin J. McAnearMr. Justin J. McAnear (Age 47)
    Chief Financial Officer
    Comp: $535.91k
  • Mr. Eric S. Whitaker Esq. (Age 56)
    Chief Legal Officer
    Comp: $558.97k
  • Mr. James L. Wilbur Ph.D. (Age 58)
    Chief Commercial Officer
    Comp: $390.78k
  • Mr. Michael Schnall-Levin
    Founding Scientist & CTO
  • Ms. Cassie Corneau
    Mang. of Investor Relations and Strategic Fin.
  • Ms. Rebecca Port
    Chief People Officer
  • Mr. James Bryant
    Director of Legal
  • Mr. Nikhil Rao
    Director of Product Management













TXG Stock - Frequently Asked Questions

Should I buy or sell 10x Genomics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TXG shares.
View TXG analyst ratings
or view top-rated stocks.

What is 10x Genomics' stock price forecast for 2023?

9 Wall Street research analysts have issued 1-year target prices for 10x Genomics' stock. Their TXG share price forecasts range from $25.00 to $75.00. On average, they anticipate the company's stock price to reach $58.73 in the next twelve months. This suggests a possible upside of 42.0% from the stock's current price.
View analysts price targets for TXG
or view top-rated stocks among Wall Street analysts.

How have TXG shares performed in 2023?

10x Genomics' stock was trading at $36.44 at the beginning of the year. Since then, TXG stock has increased by 13.5% and is now trading at $41.35.
View the best growth stocks for 2023 here
.

When is 10x Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our TXG earnings forecast
.

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.14. The business earned $146.82 million during the quarter, compared to analysts' expectations of $139.97 million. 10x Genomics had a negative trailing twelve-month return on equity of 21.69% and a negative net margin of 30.31%. 10x Genomics's revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.57) EPS.

What guidance has 10x Genomics issued on next quarter's earnings?

10x Genomics updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $600.00 million-$620.00 million, compared to the consensus revenue estimate of $600.73 million.

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

(TXG) raised $297 million in an IPO on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.

What is 10x Genomics' stock symbol?

10x Genomics trades on the NASDAQ under the ticker symbol "TXG."

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (7.32%), BlackRock Inc. (4.65%), Sands Capital Management LLC (3.55%), ARK Investment Management LLC (2.68%), Brown Capital Management LLC (2.65%) and SRS Investment Management LLC (1.87%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends
.

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 10x Genomics' stock price today?

One share of TXG stock can currently be purchased for approximately $41.35.

How much money does 10x Genomics make?

10x Genomics (NASDAQ:TXG) has a market capitalization of $4.86 billion and generates $516.41 million in revenue each year. The company earns $-166,000,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How many employees does 10x Genomics have?

The company employs 1,243 workers across the globe.

How can I contact 10x Genomics?

10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The official website for the company is www.10xgenomics.com. The company can be reached via phone at 925-401-7300 or via email at investors@10xgenomics.com.

This page (NASDAQ:TXG) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -